<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Uncomplicated acute sinusitis and rhinosinusitis in adults: Treatment</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Uncomplicated acute sinusitis and rhinosinusitis in adults: Treatment</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Uncomplicated acute sinusitis and rhinosinusitis in adults: Treatment</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Zara M Patel, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Peter H Hwang, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Daniel G Deschler, MD, FACS</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Thomas M File, Jr, MD</a></dd><dt><span> </span>Deputy Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sara Swenson, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sheila Bond, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 07, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H198762308"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Acute rhinosinusitis (ARS) is defined as symptomatic inflammation of the nasal cavity and paranasal sinuses  (<a class="graphic graphic_figure graphicRef78790" href="/z/d/graphic/78790.html" rel="external">figure 1</a>) lasting less than four weeks. The term "rhinosinusitis" is preferred to "sinusitis" since inflammation of the sinuses rarely occurs without concurrent inflammation of the nasal mucosa [<a href="#rid1">1</a>].</p><p>The most common etiology of ARS is a viral infection. The clinical manifestations and diagnosis of ARS are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/6871.html" rel="external">"Acute sinusitis and rhinosinusitis in adults: Clinical manifestations and diagnosis"</a>.)</p><p>Treatment for acute viral rhinosinusitis (AVRS) focuses on symptomatic management as it typically resolves within 7 to 10 days. Bacterial infection occurs in only 0.5 to 2 percent of episodes of ARS [<a href="#rid2">2</a>]. Acute bacterial rhinosinusitis (ABRS) may also be a self-limited disease. Patients may be treated symptomatically and observed or treated with antibiotics. Rarely, patients with ABRS develop serious complications.</p><p>This topic will address the treatment of uncomplicated ARS. The treatment of complications of ABRS are discussed in the appropriate topics. As examples:</p><p class="bulletIndent1"><span class="glyph">●</span>Orbital cellulitis (see  <a class="medical medical_review" href="/z/d/html/3414.html" rel="external">"Orbital cellulitis"</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Preseptal (periorbital) cellulitis (see  <a class="medical medical_review" href="/z/d/html/16650.html" rel="external">"Preseptal cellulitis"</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Intracranial abscess (see  <a class="medical medical_review" href="/z/d/html/1279.html" rel="external">"Treatment and prognosis of bacterial brain abscess"</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Meningitis (see  <a class="medical medical_review" href="/z/d/html/1290.html" rel="external">"Initial therapy and prognosis of community-acquired bacterial meningitis in adults"</a>)</p><p></p><p>The treatment of nosocomial bacterial sinusitis and acute invasive fungal sinusitis are also discussed separately. (See  <a class="medical medical_review" href="/z/d/html/2452.html" rel="external">"Fungal rhinosinusitis", section on 'Treatment'</a> and  <a class="medical medical_review" href="/z/d/html/1644.html" rel="external">"Complications of the endotracheal tube following initial placement: Prevention and management in adult intensive care unit patients", section on 'Sinusitis'</a>.)</p><p class="headingAnchor" id="H17857310"><span class="h1">ACUTE VIRAL RHINOSINUSITIS</span><span class="headingEndMark"> — </span>Patients with acute viral rhinosinusitis (AVRS) should be managed with supportive care [<a href="#rid3">3</a>]. There are no treatments to shorten the clinical course of the disease. (See <a class="local">'Symptomatic management'</a> below.)</p><p class="headingAnchor" id="H547040285"><span class="h2">Natural history</span><span class="headingEndMark"> — </span>AVRS may not completely resolve within 10 days but is expected to improve. Patients who fail to improve after ≥10 days of symptomatic management are more likely to have acute bacterial rhinosinusitis (ABRS) and should be managed as ABRS patients. (See  <a class="medical medical_review" href="/z/d/html/6871.html" rel="external">"Acute sinusitis and rhinosinusitis in adults: Clinical manifestations and diagnosis", section on 'Acute bacterial rhinosinusitis'</a> and <a class="local">'Acute bacterial rhinosinusitis'</a> below.)</p><p class="headingAnchor" id="H17857688"><span class="h2">Symptomatic management</span><span class="headingEndMark"> — </span>Symptomatic management of acute rhinosinusitis (ARS), both viral and bacterial in etiology, aims to relieve symptoms of nasal obstruction and rhinorrhea as well as the systemic signs and symptoms such as fever and fatigue. When needed, we suggest over-the-counter analgesics and antipyretics, <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a> irrigation, intranasal glucocorticoids, and potentially flavonoids [<a href="#rid4">4</a>] for symptomatic management in patients with ARS  (<a class="graphic graphic_table graphicRef119574" href="/z/d/graphic/119574.html" rel="external">table 1</a>). <span class="utd-adt-cnt utd-adt-pathwys utd-content-120459">(Related Pathway(s):  <a class="utd-content-120459" href="/pathway/120459?topicRef=83012&amp;source=see_link">Acute rhinosinusitis: Initial management and antibiotic selection in adults</a>.)</span></p><p class="headingAnchor" id="H1205144"><span class="h3">Analgesics and antipyretics</span><span class="headingEndMark"> — </span>Over-the-counter analgesics and antipyretics such as nonsteroidal antiinflammatory drugs (NSAIDs) and <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a> can be used for pain and fever relief as needed [<a href="#rid5">5,6</a>].</p><p class="headingAnchor" id="H1205151"><span class="h3">Saline irrigation</span><span class="headingEndMark"> — </span>Mechanical irrigation with buffered, physiologic, or hypertonic <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a> may reduce the need for pain medication and improve overall patient comfort, particularly in patients with frequent sinus infections. The evidence supporting the use of saline irrigation is limited but indicates possible benefits for symptom relief with minor adverse effects, such as nasal burning and irritation [<a href="#rid7">7</a>]. It is important that irrigants be prepared from sterile or bottled water as there have been reports of amebic encephalitis due to tap water rinses [<a href="#rid8">8</a>]. Instructions for preparing a rinse solution are shown in the table  (<a class="graphic graphic_table graphicRef71059" href="/z/d/graphic/71059.html" rel="external">table 2</a>).</p><p class="headingAnchor" id="H1205158"><span class="h3">Intranasal glucocorticoids</span><span class="headingEndMark"> — </span>Studies have shown small symptomatic benefits and minimal adverse effects with short-term use of intranasal glucocorticoids for patients with both viral and bacterial ARS [<a href="#rid5">5,6</a>]. Intranasal glucocorticoids are likely to be most beneficial for patients with underlying allergic rhinitis. The theoretic mechanism of action is a decrease in mucosal inflammation that allows improved sinus drainage.</p><p>A meta-analysis of three studies involving patients with ARS diagnosed by symptoms and confirmed by radiologic or endoscopic studies found that use of intranasal steroids increased the rate of symptom response compared with placebo (risk ratio 1.11, 95% CI 1.04-1.18) [<a href="#rid9">9</a>]. A higher dose of intranasal glucocorticoids had a stronger effect on symptom improvement. When used as an adjunct to antibiotic therapy in the treatment of ABRS, a meta-analysis of placebo-controlled trials suggests that 15 patients would need to be treated with intranasal glucocorticoids to improve clinical symptoms in one patient [<a href="#rid6">6</a>].</p><p class="headingAnchor" id="H17851666"><span class="h3">Other</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Intranasal </strong><a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a><strong> spray</strong> – Sterile intranasal saline spray may temporarily improve nasal passage patency by moisturizing and loosening secretions. This approach may be useful in combination with intranasal glucocorticoids. The major disadvantages are that some patients may find this to be uncomfortable or difficult. Saline must also be sterile.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Intranasal </strong><a class="drug drug_general" data-topicid="8570" href="/z/d/drug information/8570.html" rel="external">ipratropium</a><strong> bromide</strong> – Intranasal ipratropium bromide is an anticholinergic spray that can help reduce rhinorrhea in patients with concurrent common cold symptoms. It may not have significant effect on nasal congestion. (See  <a class="medical medical_review" href="/z/d/html/6868.html" rel="external">"The common cold in adults: Treatment and prevention", section on 'Intranasal ipratropium bromide'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Oral decongestants</strong> – Oral decongestants may be useful when Eustachian tube dysfunction is a factor for patients with AVRS. These patients may benefit from a short course (three to five days) of oral decongestants. Oral decongestants should be used with caution in patients with cardiovascular disease, hypertension, angle-closure glaucoma, or bladder neck obstruction [<a href="#rid10">10</a>]. (See  <a class="medical medical_review" href="/z/d/html/14608.html" rel="external">"Eustachian tube dysfunction"</a> and  <a class="medical medical_review" href="/z/d/html/14608.html" rel="external">"Eustachian tube dysfunction", section on 'Medical management'</a>.)</p><p></p><p class="bulletIndent1">In other patients, there is no evidence that oral decongestants are efficacious in decreasing symptoms of ARS, and they have many adverse side effects  (<a class="graphic graphic_table graphicRef65742" href="/z/d/graphic/65742.html" rel="external">table 3</a>) [<a href="#rid5">5,6</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Intranasal decongestants</strong> – Intranasal decongestants are often used as symptomatic therapies by patients. These agents, such as <a class="drug drug_general" data-topicid="10186" href="/z/d/drug information/10186.html" rel="external">oxymetazoline</a>, may provide a subjective sense of improved nasal patency. However, there is no evidence to support their use for ARS [<a href="#rid5">5,6</a>]. There is also concern that intranasal decongestants themselves may provoke mucosal inflammation, at least in an experimental animal model [<a href="#rid11">11</a>]. If used, topical decongestants should be used sparingly for no more than three consecutive days to avoid rebound congestion, addiction, and mucosal damage associated with long-term use [<a href="#rid12">12</a>]. (See  <a class="medical medical_review" href="/z/d/html/7533.html" rel="external">"An overview of rhinitis", section on 'Nasal decongestant sprays'</a> and  <a class="medical medical_review" href="/z/d/html/7532.html" rel="external">"Chronic nonallergic rhinitis", section on 'Management of rhinitis medicamentosa'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antihistamines</strong> – Antihistamines are frequently used for symptom relief due to their drying effects; however, there are no studies investigating their efficacy for ARS [<a href="#rid5">5,6</a>]. Over-drying of the mucosa may lead to further discomfort. Additionally, antihistamines (particularly first-generation medications) are often associated with adverse effects (drowsiness, xerostomia) [<a href="#rid6">6</a>]. (See  <a class="medical medical_review" href="/z/d/html/7526.html" rel="external">"Pharmacotherapy of allergic rhinitis", section on 'Adverse effects and safety'</a> and  <a class="medical medical_review" href="/z/d/html/7526.html" rel="external">"Pharmacotherapy of allergic rhinitis", section on 'Adverse effects'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mucolytics</strong> – Mucolytics such as <a class="drug drug_general" data-topicid="8503" href="/z/d/drug information/8503.html" rel="external">guaifenesin</a> serve to thin secretions and may promote ease of mucus drainage and clearance; however, no published trials exist to support their use in ARS [<a href="#rid5">5</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Steam inhalation or “tenting”</strong> – Inhalation of warm, humidified air (steam), may provide patients with a transient sense of relief of congestion, but there is no evidence that it will shorten the duration or severity of symptoms [<a href="#rid13">13,14</a>]. If steam is used, care should be taken to ensure that the source of steam is clean, without mold or other contaminants.</p><p></p><p class="headingAnchor" id="H547040381"><span class="h1">ACUTE BACTERIAL RHINOSINUSITIS</span><span class="headingEndMark"> — </span>In addition to supportive care, options for the outpatient management of uncomplicated acute bacterial rhinosinusitis (ABRS) are observation or antibiotics depending on patient follow-up  (<a class="graphic graphic_algorithm graphicRef106157" href="/z/d/graphic/106157.html" rel="external">algorithm 1</a>).</p><p>Guidelines for the management of sinusitis have been issued by the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.entnet.org%2Fquality-practice%2Fquality-products%2Fclinical-practice-guidelines%2Fadult-sinusitis%2F&amp;token=NFnGNyR%2FxpcUCOC%2BSmzGJuhM7JjVFrBJ1phQl0OC0bPmxN3vob%2BsK1vT%2BlqBc1qM%2FE%2Fcjw46ViHKmiK3GfpvepG7olhzXfIakmA9kUwbi8Fwrhw56QmPMiff6u%2FQ6lim&amp;TOPIC_ID=83012" target="_blank">American Academy of Otolaryngology-Head and Neck Surgery</a> (AAO-HNS; 2015) and the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Facademic.oup.com%2Fcid%2Farticle%2F54%2F8%2Fe72%2F367144&amp;token=i%2BIJbZ3566jvLjqylaYc8D23O%2Fk2m8qRPrU4n4GJeOnfZrj7NQ12FuodrF7eHZqGvaLOJlx%2B7D6Kov0fbhb%2Fdw%3D%3D&amp;TOPIC_ID=83012" target="_blank">Infectious Disease Society of America</a> (IDSA; 2012). Our recommendations for management are largely consistent with those of the AAO-HNS.</p><p class="headingAnchor" id="H547041319"><span class="h2">Natural history</span><span class="headingEndMark"> — </span>Many patients with ABRS have self-limited disease that resolves without antibiotic therapy. Patients rarely develop complications of bacterial infection beyond the nasal cavity into the central nervous system, orbit, or surrounding tissues. Patients treated with antibiotics may have a shorter course of illness; however, they also experience more adverse events. (See <a class="local">'Observation and symptomatic management'</a> below and <a class="local">'Antibiotics'</a> below.)</p><p class="headingAnchor" id="H547041326"><span class="h2">Indications for urgent referral</span><span class="headingEndMark"> — </span>Urgent early referral is essential for patients with symptoms that are concerning for complicated ABRS or have evidence of complications on imaging. These include patients with high, persistent fevers &gt;102°F; periorbital edema, inflammation, or erythema; cranial nerve palsies; abnormal extraocular movements; proptosis; vision changes (double vision or impaired vision); severe headache; altered mental status; or meningeal signs. (See  <a class="medical medical_review" href="/z/d/html/6871.html" rel="external">"Acute sinusitis and rhinosinusitis in adults: Clinical manifestations and diagnosis", section on 'Complications'</a> and  <a class="medical medical_review" href="/z/d/html/6871.html" rel="external">"Acute sinusitis and rhinosinusitis in adults: Clinical manifestations and diagnosis", section on 'Complicated acute bacterial rhinosinusitis'</a>.)</p><p class="headingAnchor" id="H547040790"><span class="h2">Observation and symptomatic management</span><span class="headingEndMark"> — </span>We suggest observation (watchful waiting for a seven-day period after clinician diagnosis) with symptomatic management for immunocompetent patients with ABRS who have good follow-up (assurance that antibiotic therapy can be started if the patient does not improve or worsens)  (<a class="graphic graphic_algorithm graphicRef106157" href="/z/d/graphic/106157.html" rel="external">algorithm 1</a>) [<a href="#rid5">5</a>]. The symptomatic management of ABRS is similar to that of acute viral rhinosinusitis (AVRS)  (<a class="graphic graphic_table graphicRef119574" href="/z/d/graphic/119574.html" rel="external">table 1</a>). (See <a class="local">'Symptomatic management'</a> above.) <span class="utd-adt-cnt utd-adt-pathwys utd-content-120459">(Related Pathway(s):  <a class="utd-content-120459" href="/pathway/120459?topicRef=83012&amp;source=see_link">Acute rhinosinusitis: Initial management and antibiotic selection in adults</a>.)</span></p><p>For patients who do not have good follow-up, we start antibiotic therapy at the time of diagnosis. We also start antibiotics for patients with a clinical diagnosis of ABRS whose symptoms worsen or fail to improve within the seven-day observation period  (<a class="graphic graphic_algorithm graphicRef106157" href="/z/d/graphic/106157.html" rel="external">algorithm 1</a>). (See <a class="local">'Antibiotics'</a> below.)</p><p>There are also a variety of reasons for patients to have a suppressed immune system, and treatment decisions for immunocompromised patients should be made on a case-by-case basis. They may warrant immediate antibiotic treatment and/or specialist referral.</p><p>Guidelines from a multidisciplinary expert panel in 2015 recommend that patients with uncomplicated ABRS (regardless of severity of symptoms) may be managed symptomatically and observed if they have good follow-up [<a href="#rid5">5</a>]. The guidelines suggest that factors such as age, general state of health, and comorbidities should be considered when choosing this option. These guidelines differ from the 2012 IDSA guidelines, which recommend initiation of antibiotics for those with persistent symptoms or signs compatible with acute rhinosinusitis (ARS) lasting for ≥10 days without any evidence of clinical improvement <strong>or</strong> onset with severe symptoms or signs of high fever (≥39°C [102°F]) and purulent nasal discharge or facial pain lasting for at least three to four consecutive days at the beginning of the illness <strong>or</strong> worsening symptoms or signs for three to four days characterized by the new onset of fever, headache, or increase in nasal discharge following a typical viral upper respiratory infection that lasted five to six days and were initially improving ("double sickening") [<a href="#rid6">6</a>]. We prefer to provide an option for continued observation in patients with uncomplicated ABRS as many patients with ABRS improve without antibiotic therapy.</p><p>ABRS may be a self-limited disease, and patients may improve without antibiotic therapy. Systematic reviews and meta-analyses have found that many patients with clinically diagnosed ABRS improve without antibiotic therapy within two weeks [<a href="#rid15">15</a>]. For example, a 2014 systematic review of randomized trials in immunocompetent patients with maxillary sinusitis found that 80 percent of patients not treated with antibiotics improved within two weeks [<a href="#rid16">16</a>]. A 2018 systematic review of 15 randomized trials including over 3000 immunocompetent patients with uncomplicated ARS found that nearly half of patients improved by one week, and two-thirds by two weeks, irrespective of antibiotic therapy [<a href="#rid17">17</a>]. Additionally, compared with placebo, patients who receive antibiotics have more adverse events [<a href="#rid17">17,18</a>]. However, the rates of spontaneous recovery for patients with ABRS are likely to be lower than reported in these analyses, as trials generally diagnose ABRS by clinical criteria and are likely to include some patients with AVRS. (See <a class="local">'Antibiotics'</a> below.)</p><p class="headingAnchor" id="H17857080"><span class="h2">Antibiotics</span><span class="headingEndMark"> — </span>For patients who do not have good follow-up, we initiate antibiotic therapy upon the diagnosis of ABRS  (<a class="graphic graphic_algorithm graphicRef106157" href="/z/d/graphic/106157.html" rel="external">algorithm 1</a> and <a class="graphic graphic_algorithm graphicRef106156" href="/z/d/graphic/106156.html" rel="external">algorithm 2</a>). In addition, antibiotics should also be started in patients who have been managed with observation who have worsening symptoms or fail to improve within a seven-day period after clinician diagnosis. <span class="utd-adt-cnt utd-adt-pathwys utd-content-120459">(Related Pathway(s):  <a class="utd-content-120459" href="/pathway/120459?topicRef=83012&amp;source=see_link">Acute rhinosinusitis: Initial management and antibiotic selection in adults</a>.)</span></p><p>Treatment decisions for immunocompromised patients should be made on a case-by-case basis. Such patients may warrant immediate antibiotic treatment and/or specialist referral. In addition, treatment decisions for patients with other comorbidities that can affect immune function (eg, diabetes) should be individualized as there are insufficient data to determine which patients will benefit most from early initiation of antibiotics rather than watchful waiting [<a href="#rid19">19</a>].</p><p>Meta-analyses have consistently found that, compared with placebo, patients with ABRS may benefit from antibiotics at the cost of increased adverse events [<a href="#rid6">6,16,20-22</a>]. Estimates of the number needed to treat to benefit range from 13 to 18 patients, while the number needed to harm is approximately eight patients [<a href="#rid5">5,6,20,21</a>].</p><p>Other meta-analyses have estimated cure or symptom improvement. One meta-analysis found that, compared with placebo, patients treated with antibiotics had a higher cure rate or symptom improvement at 7 to 15 days (odds ratio [OR] 1.64, 95% CI 1.35-2.0), with moderate magnitude of effect at the expense of an increase in adverse effects with antibiotic therapy [<a href="#rid22">22</a>]. Another found that, compared with placebo, antibiotic therapy with penicillin or <a class="drug drug_general" data-topicid="8673" href="/z/d/drug information/8673.html" rel="external">amoxicillin</a> decreased clinical failure at 7 to 15 days (lack of full recovery or improvement; risk ratio [RR] 0.66, 95% CI 0.47-0.94), but the clinical benefit was small and adverse events were more common with antibiotic treatment [<a href="#rid16">16</a>].</p><p>However, the studies in these meta-analyses have limitations. Many of the studies are likely to have included patients with AVRS as most studies used clinical criteria for diagnosis of ABRS without culture confirmation. Including patients with AVRS would make antibiotics appear less effective for ABRS. Also, studies have not generally distinguished the effectiveness of antibiotics based on symptom severity.</p><p>Additionally, comparative studies of antibiotics for the treatment of ABRS are limited as many studies likely include patients with AVRS. The significant rate of spontaneous recovery in studies decreases the ability of studies to differentiate between antibiotics (the apparent response to less-effective antibiotics is greater than would be seen in a more strictly defined ABRS population; conversely, the relative effectiveness of more appropriate antibiotics is diminished).</p><p class="headingAnchor" id="H547041653"><span class="h3">Initial therapy</span><span class="headingEndMark"> — </span>Most patients with ABRS do not have culture data to guide antibiotic therapy, and treatment is initiated empirically  (<a class="graphic graphic_algorithm graphicRef106156" href="/z/d/graphic/106156.html" rel="external">algorithm 2</a>). The choice of antibiotic is based on the most common bacteria associated with ABRS  (<a class="graphic graphic_table graphicRef81702" href="/z/d/graphic/81702.html" rel="external">table 4</a>) as there is limited evidence to guide therapy [<a href="#rid23">23-28</a>]. Routine coverage for <em>Staphylococcus aureus</em> or methicillin-resistant <em>S. aureus</em> (MRSA) is not indicated at this time. Despite the prevalence of staphylococcal colonization in the middle meatus in health adults, <em>S. aureus</em> remains an uncommon cause of ABRS [<a href="#rid29">29</a>]. (See  <a class="medical medical_review" href="/z/d/html/6871.html" rel="external">"Acute sinusitis and rhinosinusitis in adults: Clinical manifestations and diagnosis", section on 'Acute bacterial rhinosinusitis'</a>.)</p><p>For most patients, we suggest initial empiric treatment with either <a class="drug drug_general" data-topicid="8673" href="/z/d/drug information/8673.html" rel="external">amoxicillin</a> or <a class="drug drug_general" data-topicid="8676" href="/z/d/drug information/8676.html" rel="external">amoxicillin-clavulanate</a>. We treat patients with risk factors for resistance with high-dose amoxicillin-clavulanate. (See  <a class="medical medical_review" href="/z/d/html/6871.html" rel="external">"Acute sinusitis and rhinosinusitis in adults: Clinical manifestations and diagnosis", section on 'Acute bacterial rhinosinusitis'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients without risk factors for pneumococcal resistance</strong> – Either <a class="drug drug_general" data-topicid="8673" href="/z/d/drug information/8673.html" rel="external">amoxicillin</a> (500 mg orally three times daily or 875 mg orally twice daily) or <a class="drug drug_general" data-topicid="8676" href="/z/d/drug information/8676.html" rel="external">amoxicillin-clavulanate</a> (500 mg/125 mg orally three times daily or 875 mg/125 mg orally twice daily) is appropriate initial therapy for patients with ABRS who do not have risk factors for resistance  (<a class="graphic graphic_table graphicRef105611" href="/z/d/graphic/105611.html" rel="external">table 5</a> and <a class="graphic graphic_algorithm graphicRef106156" href="/z/d/graphic/106156.html" rel="external">algorithm 2</a>) [<a href="#rid5">5,30</a>]. The addition of clavulanate to amoxicillin improves coverage for ampicillin-resistant <em>Haemophilus influenzae</em> as well as <em>Moraxella catarrhalis</em>.</p><p></p><p class="bulletIndent1">The evidence to support the use of <a class="drug drug_general" data-topicid="8676" href="/z/d/drug information/8676.html" rel="external">amoxicillin-clavulanate</a> rather than <a class="drug drug_general" data-topicid="8673" href="/z/d/drug information/8673.html" rel="external">amoxicillin</a> is stronger in children than adults [<a href="#rid6">6</a>]. However, there is increasing emergence of antimicrobial resistance among respiratory pathogens, including <em>Streptococcus pneumoniae</em> and <em>H. influenzae</em>. Resistance rates vary regionally, with the prevalence of <em>H. influenzae </em>resistance ranging from 27 to 43 percent in the United States [<a href="#rid6">6</a>]. Additionally, the introduction of routine conjugated pneumococcal vaccination in children has changed the spectrum of bacterial infection. In both adults and children, the percentage of ABRS due to <em>S. pneumoniae</em> has decreased while the proportion due to <em>H. influenzae </em>has increased.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients with risk factors for pneumococcal resistance</strong> – High-dose <a class="drug drug_general" data-topicid="8676" href="/z/d/drug information/8676.html" rel="external">amoxicillin-clavulanate</a> (2 g/125 mg extended-release tablets orally twice daily) is appropriate initial therapy for patients who are at higher risk for pneumococcal resistance or poor outcomes  (<a class="graphic graphic_algorithm graphicRef106156" href="/z/d/graphic/106156.html" rel="external">algorithm 2</a>) [<a href="#rid5">5,6</a>]. Risk factors for resistance and/or poor outcomes include  (<a class="graphic graphic_table graphicRef105611" href="/z/d/graphic/105611.html" rel="external">table 5</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Living in geographic regions with rates of penicillin-nonsusceptible <em>S. pneumoniae</em> exceeding 10 percent. Local and regional histograms of bacterial resistance should be referenced to understand resistance trends in the local community.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Age ≥65 years.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Hospitalization in the last five days.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Antibiotic use in the previous month.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Immunocompromise.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Multiple comorbidities (eg, diabetes or chronic cardiac, hepatic, or renal disease).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Severe infection (eg, evidence of systemic toxicity with temperature of ≥102°F, concern for suppurative complications).</p><p></p><p class="bulletIndent1"><strong>Patients with penicillin allergy</strong> – For patients who have a penicillin allergy, the choice of initial therapy depends upon the severity of the allergy.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For any patient with a penicillin allergy, <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a> (100 mg orally twice daily or 200 mg orally daily) is a reasonable alternative to <a class="drug drug_general" data-topicid="8673" href="/z/d/drug information/8673.html" rel="external">amoxicillin</a> or <a class="drug drug_general" data-topicid="8676" href="/z/d/drug information/8676.html" rel="external">amoxicillin-clavulanate</a> for initial therapy  (<a class="graphic graphic_algorithm graphicRef106156" href="/z/d/graphic/106156.html" rel="external">algorithm 2</a>) [<a href="#rid5">5,6</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For penicillin-allergic patients who can tolerate cephalosporins, a third-generation oral cephalosporin (<a class="drug drug_general" data-topicid="9216" href="/z/d/drug information/9216.html" rel="external">cefixime</a> 400 mg daily or <a class="drug drug_general" data-topicid="9224" href="/z/d/drug information/9224.html" rel="external">cefpodoxime</a> 200 mg twice daily) prescribed with or without <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">clindamycin</a> (300 mg every six hours) is another option. Monotherapy with a third-generation cephalosporin is likely adequate for most patients, particularly those without risk factors for resistance.</p><p></p><p class="bulletIndent2">For patients with risk factors for resistance  (<a class="graphic graphic_table graphicRef105611" href="/z/d/graphic/105611.html" rel="external">table 5</a>), the addition of <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">clindamycin</a> to a cephalosporin provides improved coverage for beta-lactam-resi<em>stant S. pneumoniae</em>, although this carries an increased risk of adverse effects<em> </em>(eg,<em> Clostridioides</em> [formerly <em>Clostridium</em>] <em>difficile </em>infection).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A respiratory fluoroquinolone (<a class="drug drug_general" data-topicid="9554" href="/z/d/drug information/9554.html" rel="external">levofloxacin</a> 750 mg or 500 mg orally once daily or <a class="drug drug_general" data-topicid="10311" href="/z/d/drug information/10311.html" rel="external">moxifloxacin</a> 400 mg orally once daily) is another alternative for penicillin-allergic patients. However, fluoroquinolones should be reserved for those who have no alternative treatment options as the risk of serious adverse effects associated with fluoroquinolones generally outweighs the benefits for patients with acute sinusitis [<a href="#rid31">31</a>]. (See  <a class="medical medical_review" href="/z/d/html/490.html" rel="external">"Fluoroquinolones", section on 'Benefits and risks of use'</a>.)</p><p></p><p>Macrolides (<a class="drug drug_general" data-topicid="9273" href="/z/d/drug information/9273.html" rel="external">clarithromycin</a> or <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">azithromycin</a>) and <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a> are not recommended for empiric therapy because of high rates of resistance of <em>S. pneumoniae</em> [<a href="#rid5">5,6</a>]. This is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/7033.html" rel="external">"Resistance of <i>Streptococcus pneumoniae</i> to the macrolides, azalides, and lincosamides"</a> and  <a class="medical medical_review" href="/z/d/html/7028.html" rel="external">"Resistance of <i>Streptococcus pneumoniae</i> to the fluoroquinolones, doxycycline, and trimethoprim-sulfamethoxazole"</a>.)</p><p>Antibiotic therapy for patients with nosocomial sinusitis and pregnant women with sinusitis are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4793.html" rel="external">"Approach to the pregnant patient with a respiratory infection", section on 'Acute sinusitis'</a> and  <a class="medical medical_review" href="/z/d/html/1644.html" rel="external">"Complications of the endotracheal tube following initial placement: Prevention and management in adult intensive care unit patients", section on 'Sinusitis'</a>.)</p><p class="headingAnchor" id="H348017228"><span class="h4">Duration</span><span class="headingEndMark"> — </span>Patients who are improving on initial antibiotic therapy should be treated for a course of five to seven days [<a href="#rid5">5,6</a>]. This shorter course is reasonable as the available evidence suggests that response rates are similar and associated with fewer adverse events than longer courses [<a href="#rid5">5,6</a>].</p><p>In one meta-analysis of 12 randomized trials of ABRS in adults, no difference was noted in response rates or relapse rates comparing short courses (3 to 7 days) and longer courses (6 to 10 days) of antibiotics [<a href="#rid32">32</a>]. Rates of adverse events were lower for 5-day compared with 10-day courses. However, there was heterogeneity in the trials in terms of symptom duration and use of adjunctive medications.</p><p class="headingAnchor" id="H3816048021"><span class="h3">Failure of initial therapy</span><span class="headingEndMark"> — </span>Patients who have worsening symptoms or fail to have improvement within seven days on initial therapy should have the diagnosis of ABRS confirmed  (<a class="graphic graphic_algorithm graphicRef106156" href="/z/d/graphic/106156.html" rel="external">algorithm 2</a>) [<a href="#rid5">5</a>]. The diagnosis can be clinically confirmed if symptoms continue to be consistent with ABRS. While imaging is not indicated for most patients with uncomplicated ABRS, imaging is reasonable in patients who fail initial therapy (particularly if the initial agent was a respiratory fluoroquinolone) and whose symptoms are either not completely consistent with ABRS or are worrisome for possible complication to either confirm sinusitis and/or evaluate for alternative diagnosis. (See  <a class="medical medical_review" href="/z/d/html/6871.html" rel="external">"Acute sinusitis and rhinosinusitis in adults: Clinical manifestations and diagnosis", section on 'Acute bacterial rhinosinusitis'</a> and  <a class="medical medical_review" href="/z/d/html/6871.html" rel="external">"Acute sinusitis and rhinosinusitis in adults: Clinical manifestations and diagnosis"</a>.) <span class="utd-adt-cnt utd-adt-pathwys utd-content-120457">(Related Pathway(s):  <a class="utd-content-120457" href="/pathway/120457?topicRef=83012&amp;source=see_link">Acute bacterial rhinosinusitis: Evaluation and management for adults who have failed initial antibiotic treatment</a>.)</span></p><p>An alternative treatment strategy is indicated for patients with confirmed uncomplicated ABRS whose symptoms worsen or fail to show some improvement with seven days of antibiotic therapy [<a href="#rid5">5</a>].</p><p>There are limited data to guide antibiotic selection for patients who do not respond to initial antibiotic treatment [<a href="#rid5">5,6</a>]. In general, treatment options for patients who fail to improve with initial therapy should have a broader spectrum of activity and/or be in a different drug class than the initial agent used. Choice of therapy thus depends on initial antibiotic therapy. Reasonable options include:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8676" href="/z/d/drug information/8676.html" rel="external">Amoxicillin-clavulanate</a> 2 g/125 mg extended-release tablets orally twice daily</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9554" href="/z/d/drug information/9554.html" rel="external">Levofloxacin</a> 500 or 750 mg orally once daily</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10311" href="/z/d/drug information/10311.html" rel="external">Moxifloxacin</a> 400 mg orally once daily</p><p></p><p>For penicillin-allergic patients, options include:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">Doxycycline</a> 100 mg orally twice daily or 200 mg orally daily</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9554" href="/z/d/drug information/9554.html" rel="external">Levofloxacin</a> 500 or 750 mg orally once daily</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10311" href="/z/d/drug information/10311.html" rel="external">Moxifloxacin</a> 400 mg orally once daily</p><p></p><p>As noted above, fluoroquinolones should be reserved for those who have no alternative treatment options as the risk of serious adverse effects associated with fluoroquinolones generally outweigh the benefits for patients with acute sinusitis [<a href="#rid31">31</a>] (see  <a class="medical medical_review" href="/z/d/html/490.html" rel="external">"Fluoroquinolones", section on 'Benefits and risks of use'</a>). A third-generation cephalosporin plus <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">clindamycin</a> is an alternative to fluoroquinolones; this regimen offers broader-spectrum coverage than <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a> but offers no particular advantage over <a class="drug drug_general" data-topicid="8676" href="/z/d/drug information/8676.html" rel="external">amoxicillin-clavulanate</a>. Use of clindamycin also carries increased risk of <em>C. difficile</em> infection.</p><p>We typically treat patients who show improvement during the first week of therapy for 7 to 10 days.</p><p>Reasons for treatment failure include resistant pathogens, inadequate dosing, structural abnormalities, or a noninfectious etiology [<a href="#rid6">6</a>]. Experimental evidence indicates bacterial eradication by day 3 [<a href="#rid33">33,34</a>], and studies have correlated clinical and bacteriologic response [<a href="#rid35">35</a>]. Although older adults or those with multiple comorbidities may take longer to resolve infection, such individuals should also show some symptom improvement within five days of initiating antibiotic therapy for ABRS [<a href="#rid6">6</a>].</p><p class="headingAnchor" id="H1465616123"><span class="h3">Failure of multiple oral antibiotic courses</span><span class="headingEndMark"> — </span>Patients should respond to a second course of appropriate antibiotic therapy within seven days of initiation. Patients who fail a second treatment course should have imaging and be referred for further evaluation  (<a class="graphic graphic_algorithm graphicRef106156" href="/z/d/graphic/106156.html" rel="external">algorithm 2</a>) [<a href="#rid5">5,6</a>]. A noncontrast computed tomography (CT) scan is appropriate in the evaluation of treatment-resistant sinusitis to evaluate for anatomic blockage [<a href="#rid36">36</a>]. Patients with anatomic abnormalities may require surgery. Patients should also be referred for sinus cultures either by direct aspirate or endoscopy of the middle meatus.</p><p class="headingAnchor" id="H11974633"><span class="h3">Relapse after oral therapy</span><span class="headingEndMark"> — </span>Recurrence of symptoms within two weeks of response to initial oral treatment usually represents inadequate eradication of infection. Patients who had a good response to initial oral therapy and who have mild symptoms can be treated with a longer course of the same antibiotic. Patients whose relapse is moderate to severe, however, are more likely to have resistant organisms and require a change in the drug selected and/or imaging. (See <a class="local">'Initial therapy'</a> above and <a class="local">'Failure of initial therapy'</a> above and <a class="local">'Failure of multiple oral antibiotic courses'</a> above.)</p><p>Patients with relapse should be treated with antibiotics for at least 7 to 10 days. If symptoms persist despite a repeat 7- to 10-day course of antibiotics, referral is warranted.</p><p class="headingAnchor" id="H17851767"><span class="h2">Systemic glucocorticoids not indicated</span><span class="headingEndMark"> — </span>We suggest not using systemic glucocorticoids in the treatment of ABRS. When given in addition to antibiotics, oral glucocorticoids may shorten the time to symptom resolution or improvement, although the benefits are small and, unlike topical glucocorticoids, systemic glucocorticoids pose a potential risk for side effects that outweighs the clinical benefits. (See  <a class="medical medical_review" href="/z/d/html/7988.html" rel="external">"Major adverse effects of systemic glucocorticoids"</a>.)</p><p>A 2014 meta-analysis evaluated five randomized trials in 1193 adults with acute sinusitis. Four trials evaluated the benefits of systemic glucocorticoids in addition to antibiotics (three trials compared antibiotics plus glucocorticoids with antibiotics plus placebo, one trial compared antibiotics plus glucocorticoids with antibiotics plus a nonsteroidal antiinflammatory), and one trial compared systemic glucocorticoids with placebo. Patients receiving systemic glucocorticoids were more likely to have resolution or improvement in symptoms at three to seven days (RR 1.3, 95% CI 1.1-1.6), although there was a lack of benefit at days 4 to 14 [<a href="#rid37">37</a>]. A 2015 meta-analysis including only the four trials where antibiotics were prescribed demonstrated similar results for short-term improvement (improved symptom control at three to seven days with glucocorticoids; RR 1.4, 95% CI 1.1-1.8) [<a href="#rid38">38</a>]. These data, however, are limited by methodologic problems including potential for attrition bias and the lack of long-term follow-up on the effects of steroids.</p><p class="headingAnchor" id="H3384964960"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/109633.html" rel="external">"Society guideline links: Acute rhinosinusitis"</a>.)</p><p class="headingAnchor" id="H45934157"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/15535.html" rel="external">"Patient education: Sinusitis in adults (The Basics)"</a> and  <a class="medical medical_basics" href="/z/d/html/84035.html" rel="external">"Patient education: What you should know about antibiotics (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topic (see  <a class="medical medical_patient" href="/z/d/html/4009.html" rel="external">"Patient education: Acute sinusitis (sinus infection) (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H11976252"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Natural history of AVRS</strong> – Acute viral rhinosinusitis (AVRS) is expected to improve or resolve within 10 days. Patients with AVRS should be managed with supportive care. Patients who fail to improve after ≥10 days of symptomatic management are more likely to have acute bacterial rhinosinusitis (ABRS) and should be managed as ABRS. (See <a class="local">'Acute viral rhinosinusitis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Symptomatic management of ARS</strong> – Symptomatic management of acute rhinosinusitis (ARS) aims to relieve symptoms of nasal obstruction and rhinorrhea. For patients with ARS, we suggest over-the-counter analgesics and <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a> nasal irrigation (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). In addition, we suggest treatment with intranasal glucocorticoids (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>), particularly for patients with underlying allergic rhinitis. Decongestants may be useful when Eustachian tube dysfunction is a factor for patients with AVRS, but they are not likely to be helpful for patients with ABRS and they have adverse side effects  (<a class="graphic graphic_table graphicRef119574" href="/z/d/graphic/119574.html" rel="external">table 1</a>). (See <a class="local">'Symptomatic management'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Observation and symptomatic management for the majority of patients with ABRS</strong> – In the majority of patients, ABRS may also be a self-limited disease. Systematic reviews and meta-analyses have found that 70 to 80 percent of immunocompetent patients improve within two weeks without antibiotic therapy.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For immunocompetent patients with ABRS who have good follow-up, we suggest symptomatic management and observation over a seven-day period after clinician diagnosis (watchful waiting) (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>). For patients who have been managed with observation who have worsening symptoms or fail to improve within the observation period, antibiotics should be started  (<a class="graphic graphic_algorithm graphicRef106157" href="/z/d/graphic/106157.html" rel="external">algorithm 1</a> and <a class="graphic graphic_algorithm graphicRef106156" href="/z/d/graphic/106156.html" rel="external">algorithm 2</a>). (See <a class="local">'Antibiotics'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients who do not have good follow-up, we initiate antibiotic therapy upon diagnosis of ABRS. (See <a class="local">'Observation and symptomatic management'</a> above and <a class="local">'Symptomatic management'</a> above.)</p><p></p><p class="bulletIndent1">There are a variety of reasons for patients to have a suppressed immune system, and treatment decisions for immunocompromised patients should be made on a case-by-case basis. Such patients may warrant immediate antibiotic treatment and/or specialist referral. Treatment decisions for patients with other comorbidities that can affect immune function (eg, diabetes) should also be individualized.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Urgent referral for complicated ABRS</strong> – For patients with symptoms that are concerning for complicated ABRS, or who have evidence of complications on imaging, urgent, early referral is essential. (See <a class="local">'Indications for urgent referral'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initial antibiotic therapy for ABRS</strong> – In light of increasing microbial resistance to antibiotics, we suggest initial empiric treatment with either <a class="drug drug_general" data-topicid="8673" href="/z/d/drug information/8673.html" rel="external">amoxicillin</a> or <a class="drug drug_general" data-topicid="8676" href="/z/d/drug information/8676.html" rel="external">amoxicillin-clavulanate</a> rather than macrolides (<a class="drug drug_general" data-topicid="9273" href="/z/d/drug information/9273.html" rel="external">clarithromycin</a> or <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">azithromycin</a>) or <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a> (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>). (See <a class="local">'Initial therapy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients without risk factors for resistance  (<a class="graphic graphic_table graphicRef105611" href="/z/d/graphic/105611.html" rel="external">table 5</a>), we treat with either <a class="drug drug_general" data-topicid="8673" href="/z/d/drug information/8673.html" rel="external">amoxicillin</a> (500 mg orally three times daily or 875 mg orally twice daily) or <a class="drug drug_general" data-topicid="8676" href="/z/d/drug information/8676.html" rel="external">amoxicillin-clavulanate</a> (500 mg/125 mg orally three times daily or 875 mg/125 mg orally twice daily).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with risk factors for pneumococcal resistance  (<a class="graphic graphic_table graphicRef105611" href="/z/d/graphic/105611.html" rel="external">table 5</a>), we treat with high-dose <a class="drug drug_general" data-topicid="8676" href="/z/d/drug information/8676.html" rel="external">amoxicillin-clavulanate</a> (2 g/125 mg extended-release tablets orally twice daily).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with a penicillin allergy, choice of initial therapy depends upon the severity of their allergy:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For any penicillin allergic patient, <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a> (100 mg orally twice daily or 200 mg orally daily) is a reasonable option for initial therapy.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For penicillin-allergic patients who can tolerate cephalosporins, using an oral third-generation cephalosporin (eg, <a class="drug drug_general" data-topicid="9216" href="/z/d/drug information/9216.html" rel="external">cefixime</a> 400 mg daily or <a class="drug drug_general" data-topicid="9224" href="/z/d/drug information/9224.html" rel="external">cefpodoxime</a> 200 mg daily) with or without oral <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">clindamycin</a> is another option. For patients with risk factors for pneumococcal resistance  (<a class="graphic graphic_table graphicRef105611" href="/z/d/graphic/105611.html" rel="external">table 5</a>), the addition of clindamycin (300 mg every six hours) to a cephalosporin provides improved coverage for beta-lactam-resistant <em>S. pneumoniae</em>.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>A respiratory fluoroquinolone (<a class="drug drug_general" data-topicid="9554" href="/z/d/drug information/9554.html" rel="external">levofloxacin</a> 500 or 750 mg orally or <a class="drug drug_general" data-topicid="10311" href="/z/d/drug information/10311.html" rel="external">moxifloxacin</a> 400 mg orally once daily) is another alternative for penicillin-allergic patients. However, fluoroquinolones should be reserved for those who have no alternative treatment options as the risk of serious adverse effects associated with fluoroquinolones generally outweigh the benefits for patients with acute sinusitis.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients who are improving on initial antibiotic therapy should be treated for five to seven days, as response rates are similar and adverse effects are fewer with this shorter course of therapy. (See <a class="local">'Duration'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Failure of initial antibiotic therapy</strong> – Patients who have worsening symptoms or fail to have improvement within seven days on initial antibiotic therapy should have the diagnosis of ABRS confirmed  (<a class="graphic graphic_algorithm graphicRef106156" href="/z/d/graphic/106156.html" rel="external">algorithm 2</a>). While imaging is not indicated for most patients with uncomplicated ABRS, imaging is reasonable in patients who fail initial therapy, in patients whose symptoms are not completely consistent with ABRS, to confirm the diagnosis of sinusitis, and/or to evaluate for a complication or an alternative diagnosis. (See <a class="local">'Failure of initial therapy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with confirmed uncomplicated ABRS who fail initial antibiotic therapy, an alternative treatment strategy is indicated. Choice of therapy will depend upon initial antibiotic therapy; the agent should have a broader spectrum of activity and/or be in a different drug class than the initial agent used. Treatment options include high-dose <a class="drug drug_general" data-topicid="8676" href="/z/d/drug information/8676.html" rel="external">amoxicillin-clavulanate</a> (2 g/125 mg extended-release tablets orally twice daily), a respiratory fluoroquinolone (<a class="drug drug_general" data-topicid="9554" href="/z/d/drug information/9554.html" rel="external">levofloxacin</a> 500 mg orally once daily or <a class="drug drug_general" data-topicid="10311" href="/z/d/drug information/10311.html" rel="external">moxifloxacin</a> 400 mg orally once daily), or a third-generation cephalosporin plus <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">clindamycin</a>.</p><p></p><p class="bulletIndent2">For penicillin-allergic patients, <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a> 100 mg orally twice daily or 200 mg orally daily is an additional alternative.</p><p></p><p class="bulletIndent2">If improvement is seen within seven days of initiation of therapy, antibiotic treatment should be continued for a total course of 7 to 10 days.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients who fail ≥2 courses of appropriate antibiotics should have imaging and be referred for further evaluation  (<a class="graphic graphic_algorithm graphicRef106156" href="/z/d/graphic/106156.html" rel="external">algorithm 2</a>). (See <a class="local">'Failure of initial therapy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Recurrence of symptoms within two weeks of response to initial treatment usually represents inadequate eradication of infection. (See <a class="local">'Relapse after oral therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Systemic glucocorticoids not indicated</strong> – For the treatment of ABRS, we suggest <strong>not</strong> using systemic glucocorticoids (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). When given in addition to antibiotics, oral glucocorticoids may shorten the time to symptom resolution or improvement, although the benefits are small and, unlike topical glucocorticoids, systemic glucocorticoids pose a potential risk for side effects that outweighs the clinical benefits.</p><p></p><p class="headingAnchor" id="H12966712"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Anne Getz, MD, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Meltzer EO, Hamilos DL, Hadley JA, et al. Rhinosinusitis: Establishing definitions for clinical research and patient care. Otolaryngol Head Neck Surg 2004; 131:S1.</a></li><li><a class="nounderline abstract_t">Fokkens WJ, Lund VJ, Mullol J, et al. European Position Paper on Rhinosinusitis and Nasal Polyps 2012. Rhinol Suppl 2012; :3 p preceding table of contents, 1.</a></li><li><a class="nounderline abstract_t">Tan T, Little P, Stokes T, Guideline Development Group. Antibiotic prescribing for self limiting respiratory tract infections in primary care: summary of NICE guidance. BMJ 2008; 337:a437.</a></li><li><a class="nounderline abstract_t">Yao J, Zhang Y, Wang XZ, et al. Flavonoids for Treating Viral Acute Respiratory Tract Infections: A Systematic Review and Meta-Analysis of 30 Randomized Controlled Trials. Front Public Health 2022; 10:814669.</a></li><li><a class="nounderline abstract_t">Rosenfeld RM, Piccirillo JF, Chandrasekhar SS, et al. Clinical practice guideline (update): adult sinusitis. Otolaryngol Head Neck Surg 2015; 152:S1.</a></li><li><a class="nounderline abstract_t">Chow AW, Benninger MS, Brook I, et al. IDSA clinical practice guideline for acute bacterial rhinosinusitis in children and adults. Clin Infect Dis 2012; 54:e72.</a></li><li><a class="nounderline abstract_t">King D, Mitchell B, Williams CP, Spurling GK. Saline nasal irrigation for acute upper respiratory tract infections. Cochrane Database Syst Rev 2015; :CD006821.</a></li><li class="breakAll">Louisiana Department of Health and Hospitals. North Louisiana woman dies from rare ameba infection. December 6, 2011 Available at: http://new.dhh.louisiana.gov/index.cfm/newsroom/detail/2332 (Accessed on January 22, 2012).</li><li><a class="nounderline abstract_t">Zalmanovici Trestioreanu A, Yaphe J. Intranasal steroids for acute sinusitis. Cochrane Database Syst Rev 2013; :CD005149.</a></li><li><a class="nounderline abstract_t">Ziment I. Management of respiratory problems in the aged. J Am Geriatr Soc 1982; 30:S36.</a></li><li><a class="nounderline abstract_t">Bende M, Fukami M, Arfors KE, et al. Effect of oxymetazoline nose drops on acute sinusitis in the rabbit. Ann Otol Rhinol Laryngol 1996; 105:222.</a></li><li><a class="nounderline abstract_t">Spector SL, Bernstein IL, Li JT, et al. Parameters for the diagnosis and management of sinusitis. J Allergy Clin Immunol 1998; 102:S107.</a></li><li><a class="nounderline abstract_t">Little P, Stuart B, Mullee M, et al. Effectiveness of steam inhalation and nasal irrigation for chronic or recurrent sinus symptoms in primary care: a pragmatic randomized controlled trial. CMAJ 2016; 188:940.</a></li><li><a class="nounderline abstract_t">Singh M, Singh M. Heated, humidified air for the common cold. Cochrane Database Syst Rev 2013; :CD001728.</a></li><li><a class="nounderline abstract_t">Hwang PH. A 51-year-old woman with acute onset of facial pressure, rhinorrhea, and tooth pain: review of acute rhinosinusitis. JAMA 2009; 301:1798.</a></li><li><a class="nounderline abstract_t">Ahovuo-Saloranta A, Rautakorpi UM, Borisenko OV, et al. Antibiotics for acute maxillary sinusitis in adults. Cochrane Database Syst Rev 2014; :CD000243.</a></li><li><a class="nounderline abstract_t">Lemiengre MB, van Driel ML, Merenstein D, et al. Antibiotics for acute rhinosinusitis in adults. Cochrane Database Syst Rev 2018; 9:CD006089.</a></li><li><a class="nounderline abstract_t">Harris AM, Hicks LA, Qaseem A, High Value Care Task Force of the American College of Physicians and for the Centers for Disease Control and Prevention. Appropriate Antibiotic Use for Acute Respiratory Tract Infection in Adults: Advice for High-Value Care From the American College of Physicians and the Centers for Disease Control and Prevention. Ann Intern Med 2016; 164:425.</a></li><li><a class="nounderline abstract_t">Rosenfeld RM. CLINICAL PRACTICE. Acute Sinusitis in Adults. N Engl J Med 2016; 375:962.</a></li><li><a class="nounderline abstract_t">Lemiengre MB, van Driel ML, Merenstein D, et al. Antibiotics for clinically diagnosed acute rhinosinusitis in adults. Cochrane Database Syst Rev 2012; 10:CD006089.</a></li><li><a class="nounderline abstract_t">Young J, De Sutter A, Merenstein D, et al. Antibiotics for adults with clinically diagnosed acute rhinosinusitis: a meta-analysis of individual patient data. Lancet 2008; 371:908.</a></li><li><a class="nounderline abstract_t">Falagas ME, Giannopoulou KP, Vardakas KZ, et al. Comparison of antibiotics with placebo for treatment of acute sinusitis: a meta-analysis of randomised controlled trials. Lancet Infect Dis 2008; 8:543.</a></li><li><a class="nounderline abstract_t">Ahovuo-Saloranta A, Borisenko OV, Kovanen N, et al. Antibiotics for acute maxillary sinusitis. Cochrane Database Syst Rev 2008; :CD000243.</a></li><li><a class="nounderline abstract_t">de Ferranti SD, Ioannidis JP, Lau J, et al. Are amoxycillin and folate inhibitors as effective as other antibiotics for acute sinusitis? A meta-analysis. BMJ 1998; 317:632.</a></li><li><a class="nounderline abstract_t">de Bock GH, Dekker FW, Stolk J, et al. Antimicrobial treatment in acute maxillary sinusitis: a meta-analysis. J Clin Epidemiol 1997; 50:881.</a></li><li><a class="nounderline abstract_t">Karageorgopoulos DE, Giannopoulou KP, Grammatikos AP, et al. Fluoroquinolones compared with beta-lactam antibiotics for the treatment of acute bacterial sinusitis: a meta-analysis of randomized controlled trials. CMAJ 2008; 178:845.</a></li><li><a class="nounderline abstract_t">Piccirillo JF, Mager DE, Frisse ME, et al. Impact of first-line vs second-line antibiotics for the treatment of acute uncomplicated sinusitis. JAMA 2001; 286:1849.</a></li><li><a class="nounderline abstract_t">Anon JB, Jacobs MR, Poole MD, et al. Antimicrobial treatment guidelines for acute bacterial rhinosinusitis. Otolaryngol Head Neck Surg 2004; 130:1.</a></li><li><a class="nounderline abstract_t">Wald ER. Staphylococcus aureus: is it a pathogen of acute bacterial sinusitis in children and adults? Clin Infect Dis 2012; 54:826.</a></li><li><a class="nounderline abstract_t">Gregory J, Huynh B, Tayler B, et al. High-Dose vs Standard-Dose Amoxicillin Plus Clavulanate for Adults With Acute Sinusitis: A Randomized Clinical Trial. JAMA Netw Open 2021; 4:e212713.</a></li><li class="breakAll">US Food and Drug Administration. FDA Drug Safety Communication: FDA advises restricting fluoroquinolone antibiotic use for certain uncomplicated infections; warns about disabling side effects that can occur together. Available at: http://www.fda.gov/Drugs/DrugSafety/ucm500143.htm (Accessed on May 26, 2016).</li><li><a class="nounderline abstract_t">Falagas ME, Karageorgopoulos DE, Grammatikos AP, Matthaiou DK. Effectiveness and safety of short vs. long duration of antibiotic therapy for acute bacterial sinusitis: a meta-analysis of randomized trials. Br J Clin Pharmacol 2009; 67:161.</a></li><li><a class="nounderline abstract_t">Ariza H, Rojas R, Johnson P, et al. Eradication of common pathogens at days 2, 3 and 4 of moxifloxacin therapy in patients with acute bacterial sinusitis. BMC Ear Nose Throat Disord 2006; 6:8.</a></li><li><a class="nounderline abstract_t">Anon JB, Paglia M, Xiang J, et al. Serial sinus aspirate samples during high-dose, short-course levofloxacin treatment of acute maxillary sinusitis. Diagn Microbiol Infect Dis 2007; 57:105.</a></li><li><a class="nounderline abstract_t">Ambrose PG, Anon JB, Owen JS, et al. Use of pharmacodynamic end points in the evaluation of gatifloxacin for the treatment of acute maxillary sinusitis. Clin Infect Dis 2004; 38:1513.</a></li><li><a class="nounderline abstract_t">Osguthorpe JD, Hadley JA. Rhinosinusitis. Current concepts in evaluation and management. Med Clin North Am 1999; 83:27.</a></li><li><a class="nounderline abstract_t">Venekamp RP, Thompson MJ, Hayward G, et al. Systemic corticosteroids for acute sinusitis. Cochrane Database Syst Rev 2014; :CD008115.</a></li><li><a class="nounderline abstract_t">Venekamp RP, Thompson MJ, Rovers MM. Systemic corticosteroid therapy for acute sinusitis. JAMA 2015; 313:1258.</a></li></ol></div><div id="topicVersionRevision">Topic 83012 Version 64.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15577816" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Rhinosinusitis: Establishing definitions for clinical research and patient care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22764607" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : European Position Paper on Rhinosinusitis and Nasal Polyps 2012.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18650239" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Antibiotic prescribing for self limiting respiratory tract infections in primary care: summary of NICE guidance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35252093" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Flavonoids for Treating Viral Acute Respiratory Tract Infections: A Systematic Review and Meta-Analysis of 30 Randomized Controlled Trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25832968" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Clinical practice guideline (update): adult sinusitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22438350" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : IDSA clinical practice guideline for acute bacterial rhinosinusitis in children and adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25892369" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Saline nasal irrigation for acute upper respiratory tract infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25892369" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Saline nasal irrigation for acute upper respiratory tract infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24293353" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Intranasal steroids for acute sinusitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7130588" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Management of respiratory problems in the aged.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8615587" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Effect of oxymetazoline nose drops on acute sinusitis in the rabbit.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9847450" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Parameters for the diagnosis and management of sinusitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27431306" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Effectiveness of steam inhalation and nasal irrigation for chronic or recurrent sinus symptoms in primary care: a pragmatic randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23733382" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Heated, humidified air for the common cold.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19336696" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : A 51-year-old woman with acute onset of facial pressure, rhinorrhea, and tooth pain: review of acute rhinosinusitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24515610" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Antibiotics for acute maxillary sinusitis in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30198548" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Antibiotics for acute rhinosinusitis in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26785402" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Appropriate Antibiotic Use for Acute Respiratory Tract Infection in Adults: Advice for High-Value Care From the American College of Physicians and the Centers for Disease Control and Prevention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27602668" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : CLINICAL PRACTICE. Acute Sinusitis in Adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23076918" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Antibiotics for clinically diagnosed acute rhinosinusitis in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18342685" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Antibiotics for adults with clinically diagnosed acute rhinosinusitis: a meta-analysis of individual patient data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18718440" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Comparison of antibiotics with placebo for treatment of acute sinusitis: a meta-analysis of randomised controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18425861" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Antibiotics for acute maxillary sinusitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9727991" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Are amoxycillin and folate inhibitors as effective as other antibiotics for acute sinusitis? A meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9291872" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Antimicrobial treatment in acute maxillary sinusitis: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18362380" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Fluoroquinolones compared with beta-lactam antibiotics for the treatment of acute bacterial sinusitis: a meta-analysis of randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11597286" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Impact of first-line vs second-line antibiotics for the treatment of acute uncomplicated sinusitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14726904" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Antimicrobial treatment guidelines for acute bacterial rhinosinusitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22198792" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Staphylococcus aureus: is it a pathogen of acute bacterial sinusitis in children and adults?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33755168" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : High-Dose vs Standard-Dose Amoxicillin Plus Clavulanate for Adults With Acute Sinusitis: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33755168" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : High-Dose vs Standard-Dose Amoxicillin Plus Clavulanate for Adults With Acute Sinusitis: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19154447" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Effectiveness and safety of short vs. long duration of antibiotic therapy for acute bacterial sinusitis: a meta-analysis of randomized trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16646958" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Eradication of common pathogens at days 2, 3 and 4 of moxifloxacin therapy in patients with acute bacterial sinusitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17178300" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Serial sinus aspirate samples during high-dose, short-course levofloxacin treatment of acute maxillary sinusitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15156435" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Use of pharmacodynamic end points in the evaluation of gatifloxacin for the treatment of acute maxillary sinusitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9927958" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Rhinosinusitis. Current concepts in evaluation and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24664368" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Systemic corticosteroids for acute sinusitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25803348" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Systemic corticosteroid therapy for acute sinusitis.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
